Nearly 29.6% of the subjects who received DMT310 had a Physician’s Global Assessment score of 0 or 1.
The pandemic pushed dermatologists to pivot to telemedicine, but new experience shows its full potential is yet to be realised.
Dupixent is the first biologic to yield positive data in this age group with uncontrolled moderate-to-severe atopic dermatitis.
Bimekizumab’s robust clinical programme has made it a much-anticipated favourite among key opinion leaders in the psoriasis space.
GlobalData's analysis of the atopic dermatitis pipeline suggests there are numerous promising agents in development for various age groups and severities.